Strategy Note /

COVID-19 aftermath and the benefit of investing in Chinese Pharmaceuticals

  • After China completed virus genome sequencing in Jan 2020, world entered a race to develop therapeutic drugs & vaccine

  • In 2020, the US biomedical market reached USD 125.2 billion, up 9.9% year-over-year

  • Although China's biomedical sector is developing rapidly, there is still a considerable gap vs the United States

Fuller Wang
14 December 2021
Published by